A new anti-diabetic compound, Montbretin A (MbA), has been approved by Health Canada for Phase 1 human trials. MbA works by inhibiting the alpha-amylase enzyme, slowing down starch breakdown and reducing blood sugar spikes in Type 2 diabetics.
GlycoNet will deliver reliable vaccine information to Canadians through interactive digital campaigns and K-12 classroom tools, supporting science literacy skills. The grant aims to promote evidence-based decision-making on vaccines across the country.
GlycoNet's GlycoCage technology involves 'caging' IBD drugs with carbohydrate molecules to prevent premature uptake in the upper GI tract. This approach aims to increase the efficacy of IBD treatments and reduce systemic side effects, such as those associated with steroid anti-inflammatory drugs.
Simonetta Sipione's research aims to clarify the therapeutic role of gangliosides in the brain, which help brain cells communicate with each other and the environment. The project seeks to develop a viable treatment that tackles the root cause of neurodegenerative diseases like Huntington's and Parkinson's.
Researchers at 48Hour Discovery will screen billions of peptides to identify hit compounds for pharmaceutical giant Merck. The two-year project aims to accelerate drug development and address unmet medical needs.
Sanfilippo syndrome is a rare genetic disorder that causes childhood dementia and premature death. Researchers are developing a new combination therapy using gene therapy and stem cells to restore metabolic defects in brain cells.
GlycoNet invests $1.3 million in new sugar research projects to tackle unmet needs in national healthcare, aiming to deliver made-in-Canada solutions and protect Canadians' lives. The funding supports various projects, including the development of gene therapies and enzymatic tools for blood supply innovation.
Researchers are exploring glycans in breast cancer cells to develop an earlier test for breast cancer through liquid biopsies. By identifying unique sugar patterns, the team aims to improve diagnostic accuracy and catch cancers at their earliest stage.
GlycoNet funds 11 collaborative research projects across Canadian institutions to develop new treatments, diagnostic tools and therapies for challenging diseases. The projects aim to improve patient care, accelerate medical innovation and mitigate healthcare burden in Canada.
GlycoNet researchers have identified a key enzyme, Agd3, critical for biofilm formation in Aspergillus fumigatus. Without this enzyme, the biofilm does not form, and the fungus is weakened. The team has also discovered a new family of carbohydrate-processing enzymes that has not been previously characterized.
GlycoNet has secured a three-year investment of $16.3 million through the Canadian Glycomics Network to accelerate carbohydrate-based healthcare treatments, vaccines, and technologies. The network aims to improve the quality of life of Canadians by delivering solutions to important health issues.
GlycoNet has awarded $885,000 in grants to seven research projects across Canada focusing on improving health outcomes for conditions such as heart disease, infections, cancer, and diabetes. The projects aim to develop accessible solutions through glycomics research.
Five Alberta-based projects have received funding from GlycoNet's Alberta Partnership Program to advance research on various health issues. The projects aim to develop new treatments for diseases such as Alzheimer's, cancer, and inflammatory intestinal diseases.
GlycoNet researchers Drs. Alexey V. Pshezhetsky and Christopher Cairo have been awarded half a million dollars to advance research on human neuraminidase inhibitors for treating cardiovascular and autoimmune diseases. The funding will support the development of novel treatments for these complex diseases.
Three Alberta startups, GlyCa BioSciences, PanTHERA CryoSolutions, and 48Hour Discovery Inc., received grants from GlycoNet worth $90,000. The funding supports patent protection and licensing activities to drive commercialization of glyco-based technologies.
Researchers have discovered a glycoside called arbutin, extracted from the bearberry plant, that can break up kidney stones. The molecule has shown remarkable ability to dissolve kidney stones in pre-clinical studies, offering a potential new treatment option for patients.
Researchers are developing fucosylation inhibitors to enhance the targeting and killing of cancer cells by making cancer therapies more selective. Dr. Robert Britton's project aims to create molecules that do not attach to themselves, allowing for improved stability and cytotoxicity.
Researchers have identified a specific sugar found on aggressive breast cancer cells that can be used as a biomarker to detect high-risk patients. This discovery aims to improve screening for early-stage breast cancer patients, reducing unnecessary treatments such as chemotherapy or radiation.
A new approach using drug-like molecules is being tested to tackle fungal infections, which cause billions of illnesses and 1.5 million deaths annually. The project uses glycan-based molecules that weaken fungal cell walls, making them more visible to the immune system.
GlycoNet researchers Matthew Macauley and John Klassen are developing a strategy to identify the molecular identity of sugars interacting with CD33 protein, strongly implicated in Alzheimer's disease. This approach may lead to therapeutic targets or diagnostic tools for preventing or treating the disease.
GlycoNet has awarded $3.5 million to researchers across Canada to explore glycomics and its impact on human health. The grants will support research into Parkinson's disease, Alzheimer's, drug-resistant fungal infections, and other areas.
PanTHERA CryoSolutions has discovered a small molecule inhibitor that prevents ice recrystallization, a process causing cell death and damage when freezing cells and tissues. This technology results in faster engraftment and increased incidence of engraftment for clinical settings.